#

+1 (917) 893 7512

  • #
  • #
  • #
#

Global PD-1 and PD-L1 Inhibitors Market: Size, Trends and Forecasts (2018-2022)

Publish Date:Aug 2018
No. of Pages:101

Format : Adobe Reader (PDF) Instant delivery

US$ 1,200.00

Scope of the Report

The report titled “Global PD-1 and PD-L1 Inhibitors Market: Size, Trends and Forecasts (2018-2022)”, provides an in depth analysis of the global PD-1 and PD-L1 inhibitors market by value, by cancer, by treatment, by region, etc. The report also provides a detailed analysis of the China PD-1 and PD-L1 inhibitors market by value, by treatment and by cancer.

The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global PD-1 and PD-L1 Inhibitors market has also been forecasted for the period 2018-2022, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

The global PD-1 and PD-L1 inhibitors market is generally dominated. Many competitors have established worldwide reputation with the multinational patients while some provide their drugs to the domestic patients. The manufacturers of the PD-1 and PD-1 inhibitors market produce different type of drugs, some manufacturers produce PD-1 inhibitors, some produce PD-L1 inhibitors while other produce combination of PD-1 and PD-L1 inhibitors.

However, the competition in the global PD-1 and PD-L1 inhibitors market is dominated by few PD-1 and PD-L1 inhibitors manufacturers. Further, key players of the PD-1 and PD-L1 inhibitors market are Bristol-Myers Squibb, Merck & Co., Inc., Roche, AstraZeneca, Jiangsu Hengrui Medicine Co. Ltd. and BeiGene, Ltd. are also profiled with their financial information and respective business strategies.

Country Coverage

China
The US
ROW

Company Coverage

Bristol-Myers Squibb
Merck & Co., Inc.
Roche
AstraZeneca
Jiangsu Hengrui Medicine Co. Ltd.
BeiGene, Ltd.

Executive Summary

Cancer is the fastest growing disease across the world and one of the most important development in the field of cancer treatment is the introduction of immune checkpoint inhibitors-agents that help to stimulate the immune system. The two main cancer treatment approaches are: Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PD-L1) inhibitors. PD-1 and PD-L1 inhibitors are both found on the surface of the cancer cells and used to kill cancer cells.

The drugs approved as a PD-1 inhibitor are Pembrolizumab and Nivolumab and the drugs approved as a PD-L1 inhibitors are atezolizumab, Durvalumab and Avelumab. There are various PD-1 and PD-L1 inhibitors which are still in experimental phase of development. The adverse effects of PD-1 and PD-L1 inhibitors are pneumonitis, colitis, skin reactions, immune thrombocytopenia, cardiac insufficiency, diarrhea, pruritus, myocarditis and pneumonitis. PD-1 and PD-L1 inhibitors has a long history with continuously evolving new generation PD-1 and PD-L1 inhibitors. The PD-1 and PD-L1 inhibitors market can be segmented on the basis of type, indications, drug and distribution channel.

The global PD-1 and PD-L1 inhibitors market has increased at a significant annual growth rate during the years 2016-2017 and projections are made that the market would rise in the next four years i.e. 2018-2022 tremendously. The PD-1 and PD-L1 inhibitors market is expected to increase due to aging population, growth in GNI per capita, growing urban population, increasing incidence of certain types of cancer, rise in the number of people with cancer, etc. Yet the market faces some challenges such as high cost of oncology treatment, side effects and toxicity, failure of clinical trials, time consuming and uncertain regulatory process, etc.

1. Executive Summary

2. Introduction

2.1 PD-1 and PD-L1 Inhibitors: An Overview

2.1.1 PD-1 and PD-L1 Inhibitors Discovery Timeline
2.1.2 PD-1/PD-L1 Inhibitors Mechanism Action and Applications
2.1.3 PD-1/PD-L1 Inhibitors in Experimental Phase of Development
2.1.4 Adverse Effects of PD-1 and PD-L1 Inhibitors

2.2 PD-1 and PD-L1 Inhibitors Segmentation: An Overview

2.2.1 PD-1 and PD-L1 Inhibitors by Type
2.2.2 PD-1 and PD-L1 Inhibitors by Indications
2.2.3 PD-1 and PD-L1 Inhibitors by Drug
2.2.4 PD-1 and PD-L1 Inhibitors by Distribution Channel

3. Global Market Analysis

3.1 Global PD-1 and PD-L1 Inhibitors Market: An Analysis

3.1.1 Global PD-1 and PD-L1 Inhibitors Market by Value
3.1.2 Global PD-1 and PD-L1 Inhibitors Market by Segments (Metastatic PD-1 and PD-L1 Inhibitors and Adjuvant PD-1 and PD-L1 Inhibitors)
3.1.3 Global PD-1 and PD-L1 Inhibitors Market by Region (The US, China and ROW)

3.2 Global PD-1 and PD-L1 Inhibitors Market: Segment Analysis

3.2.1 Global Metastatic PD-1 and PD-L1 Inhibitors Market by Value
3.2.2 Global Adjuvant PD-1 and PD-L1 Inhibitors Market by Value

4. Regional Market Analysis

4.1 China PD-1 and PD-L1 Inhibitors Market: An Analysis

4.1.1 China PD-1 and PD-L1 Inhibitors Market by Value
4.1.2 China PD-1 and PD-L1 Inhibitors Market by Cancer (Non-small Cell Lung Carcinoma, Hepatocellular Carcinoma, Gastric Cancer, Esophageal Cancer, Small Cell Lung Cancer and Others)
4.1.3 China PD-1 and PD-L1 Inhibitors Market by Treatment (1L Treatment and 2L+ Treatment)

4.2 China PD-1 and PD-L1 Inhibitors Market: Treatment Analysis

4.2.1 China 1L PD-1 and PD-L1 Inhibitors Market by Value
4.2.2 China 1L PD-1 and PD-L1 Inhibitors Market by Cancer (Non-small Cell Lung Carcinoma, Hepatocellular Carcinoma, Gastric Cancer, Esophageal Cancer, Small Cell Lung Cancer and Others)
4.2.3 China 2L+ PD-1 and PD-L1 Inhibitors Market by Value
4.2.4 China 2L+ PD-1 and PD-L1 Inhibitors Market by Cancer (Non-small Cell Lung Carcinoma, Hepatocellular Carcinoma, Gastric Cancer, Esophageal Cancer, Small Cell Lung Cancer and Others)

4.3 China PD-1 and PD-L1 Inhibitors Market: Cancer Analysis

4.3.1 China Non-small Cell Lung Cancer (NSCLC) Market by Value
4.3.2 China Non-small Cell Lung Cancer (NSCLC) Market by Treatment (1L Treatment and 2L+ Treatment)
4.3.3 China 1L and 2L+ Non-small Cell Lung Cancer (NSCLC) Treatment Market by Value
4.3.4 China Small Cell Lung Cancer (SCLC) Market by Value
4.3.5 China Small Cell Lung Cancer (SCLC) Market by Treatment (1L Treatment and 2L+ Treatment)
4.3.6 China 1L and 2L+ Small Cell Lung Cancer (SCLC) Treatment Market by Value
4.3.7 China Hepatocellular Carcinoma (HCC) Market by Value
4.3.8 China Hepatocellular Carcinoma (HCC) Market by Treatment (1L Treatment and 2L+ Treatment)
4.3.9 China 1L and 2L+ Hepatocellular Carcinoma (HCC) Treatment Market by Value 
4.3.10 China Gastric Cancer (GC) Market by Value
4.3.11 China Gastric Cancer (GC) Market by Treatment (1L Treatment and 2L+ Treatment)
4.3.12 China 1L and 2L+ Gastric Cancer (GC) Treatment Market by Value
4.3.13 China Esophageal Squamous Cell Carcinoma (ESCC) Market by Value
4.3.14 China Esophageal Squamous Cell Carcinoma (ESCC) Market by Treatment (1L Treatment and 2L+ Treatment)
4.3.15 China 1L and 2L+ Esophageal Squamous Cell Carcinoma (ESCC) Treatment Market by Value
4.3.16 China Other Cancers Market by Value
4.3.17 China Other Cancers Market by Treatment (1L Treatment and 2L+ Treatment)
4.3.18 China 1L and 2L+ Other Cancers Treatment Market by Value

4.4 The US PD-1 and PD-L1 Inhibitors Market: An Analysis

4.4.1 The US PD-1 and PD-L1 Inhibitors Market by Value

4.5 ROW PD-1 and PD-L1 Inhibitors Market: An Analysis

4.5.1 ROW PD-1 and PD-L1 Inhibitors Market by Value

5. Market Dynamics

5.1 Growth Driver

5.1.1 Aging Population 
5.1.2 Increasing GNI Per Capita 
5.1.3 Growing Urban Population
5.1.4 Increased Incidence of Certain Types of Cancer 
5.1.5 Surge in the Number of People with Cancer by Age 

5.2 Challenges

5.2.1 High Cost of Oncology Treatment
5.2.2 Side Effects and Toxicity
5.2.3 Failure of Clinical Trial
5.2.4 Time Consuming and Uncertain Regulatory Process

5.3 Market Trends

5.3.1 Rising Healthcare Awareness and Changing Lifestyle
5.3.2 Public Medical Insurance 
5.3.3 Accelerated Approval of New PD-1 and PD-L1 Inhibitors
5.3.4 Increased Consumption of Alcohol and Smoking

6. Competitive Landscape

6.1 Global PD-1 and PD-L1 Inhibitors Market: Competitive Landscape
6.2 Global PD-1 and PD-L1 Inhibitors Market Players by Phase 3 Studies
6.3 Regulatory Status of Key PD-L1 Drugs in China 

7. Company Profiles

7.1 Bristol-Myers Squibb
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategy

7.2 Merck & Co., Inc.
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategy

7.3 Roche
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategy

7.4 AstraZeneca
7.4.1 Business Overview
7.4.2 Financial Overview
7.4.3 Business Strategy

7.5 Jiangsu Hengrui Medicine Co. Ltd.
7.6 BeiGene, Ltd.
Figure 1: PD-1 and PD-L1 Inhibitors Discovery Timeline
Figure 2: PD-1/PD-L1 Inhibitors in Experimental Phase of Development
Figure 3: Adverse Effects of PD-1 and PD-L1 Inhibitors
Figure 4: PD-1 and PD-L1 Inhibitors by Type
Figure 5: PD-1 and PD-L1 Inhibitors by Indications
Figure 6: PD-1 and PD-L1 Inhibitors by Drug
Figure 7: PD-1 and PD-L1 Inhibitors by Distribution Channel
Figure 8: Global PD-1 and PD-L1 Inhibitors Market by Value; 2016-2017 (US$ Billion)
Figure 9: Global PD-1 and PD-L1 Inhibitors Market by Value; 2018-2022 (US$ Billion)
Figure 10: Global PD-1 and PD-L1 Inhibitors Market by Segments; 2017 (Percentage, %)
Figure 11: Global PD-1 and PD-L1 Inhibitors Market by Region; 2017-2018 (Percentage, %)
Figure 12: Global Metastatic PD-1 and PD-L1 Inhibitors Market by Value; 2016-2017 (US$ Billion)
Figure 13: Global Metastatic PD-1 and PD-L1 Inhibitors Market by Value; 2018-2022 (US$ Billion)
Figure 14: Global Adjuvant PD-1 and PD-L1 Inhibitors Market by Value; 2017-2022 (US$ Billion)
Figure 15: China PD-1 and PD-L1 Inhibitors Market by Value; 2018-2022 (US$ Billion)
Figure 16: China PD-1 and PD-L1 Inhibitors Market by Cancer; 2018 & 2022 (Percentage, %)
Figure 17: China PD-1 and PD-L1 Inhibitors Market by Treatment; 2018 (Percentage, %)
Figure 18: China 1L PD-1 and PD-L1 Inhibitors Market by Value; 2018-2022 (US$ Billion)
Figure 19: China 1L PD-1 and PD-L1 Inhibitors Market by Cancer; 2018 (Percentage, %)
Figure 20: China 2L+ PD-1 and PD-L1 Inhibitors Market by Value; 2018-2022 (US$ Million)
Figure 21: China 2L+ PD-1 and PD-L1 Inhibitors Market by Cancer; 2018 (Percentage, %)
Figure 22: China Non-small Cell Lung Cancer (NSCLC) Market by Value; 2018-2022 (US$ Billion)
Figure 23: China Non-small Cell Lung Cancer (NSCLC) Market by Treatment; 2018 (Percentage, %)
Figure 24: China 1L Non-small Cell Lung Cancer (NSCLC) Treatment Market by Value; 2018-2022 US$ Billion)
Figure 25: China 2L+ Non-small Cell Lung Cancer (NSCLC) Treatment Market by Value; 2018-2022 (US$ Million)
Figure 26: China Small Cell Lung Cancer (SCLC) Market by Value; 2018-2022 (US$ Million)
Figure 27: China Small Cell Lung Cancer (SCLC) Market by Treatment; 2018 (Percentage, %)
Figure 28: China 1L Small Cell Lung Cancer (SCLC) Treatment Market by Value; 2018-2022 (US$ Million)
Figure 29: China 2L+ Small Cell Lung Cancer (SCLC) Treatment Market by Value; 2018-2022 (US$ Million)
Figure 30: China Hepatocellular Carcinoma (HCC) Market by Value; 2018-2022 (US$ Million)
Figure 31: China Hepatocellular Carcinoma (HCC) Market by Treatment; 2018 (Percentage, %)
Figure 32: China 1L Hepatocellular Carcinoma (HCC) Treatment Market by Value; 2018-2022 (US$ Million)
Figure 33: China 2L+ Hepatocellular Carcinoma (HCC) Treatment Market by Value; 2018-2022 (US$ Million)
Figure 34: China Gastric Cancer (GC) Market by Value; 2018-2022 (US$ Million)
Figure 35: China Gastric Cancer (GC) Market by Treatment; 2018 (Percentage, %)
Figure 36: China 1L Gastric Cancer (GC) Treatment Market by Value; 2018-2022 (US$ Million)
Figure 37: China 2L+ Gastric Cancer (GC) Treatment Market by Value; 2018-2022 (US$ Million)
Figure 38: China Esophageal Squamous Cell Carcinoma (ESCC) Market by Value; 2018-2022 (US$ Million)
Figure 39: China Esophageal Squamous Cell Carcinoma (ESCC) Market by Treatment; 2018 (Percentage, %)
Figure 40: China 1L Esophageal Squamous Cell Carcinoma (ESCC) Treatment Market by Value; 2018-2022 (US$ Million)
Figure 41: China 2L+ Esophageal Squamous Cell Carcinoma (ESCC) Treatment Market by Value; 2018-2022 (US$ Million)
Figure 42: China Other Cancers Market by Value; 2018-2022 (US$ Million)
Figure 43: China Other Cancers Market by Treatment; 2018 (Percentage, %)
Figure 44: China 1L Other Cancers Treatment Market by Value; 2018-2022 (US$ Million)
Figure 45: China 2L+ Other Cancers Treatment Market by Value; 2018-2022 (US$ Million)
Figure 46: The US PD-1 and PD-L1 Inhibitors Market by Value; 2016-2017 (US$ Billion)
Figure 47: The US PD-1 and PD-L1 Inhibitors Market by Value; 2018-2022 (US$ Billion)
Figure 48: ROW PD-1 and PD-L1 Inhibitors Market by Value; 2016-2017 (US$ Billion)
Figure 49: ROW PD-1 and PD-L1 Inhibitors Market by Value; 2018-2022 (US$ Billion)
Figure 50: World Aging Population by Gender ; 2011-2017 (Trillion)
Figure 51: Global GNI Per Capita; 2010-2016 (US$)
Figure 52: Global Urban Population; 2011-2017 (Billion)
Figure 53: Incidence of Certain Types of Cancer; 2017
Figure 54: Number of People with Cancer by Age; 2011-2016 (Million)
Figure 55: Global Oncology Treatment Cost; 2012-2016 (US$ Billion)
Figure 56: Global PD-1 and PD-L1 Inhibitors Market Players by Phase 3 Studies; 2017 (Percentage, %)
Figure 57: Bristol-Myers Squibb Total Revenue; 2013-2017 (US$ Billion)
Figure 58: Bristol-Myers Squibb Total Revenue by Products; 2017 (Percentage, %)
Figure 59: Bristol-Myers Squibb Total Revenue by Region; 2017 (Percentage, %)
Figure 60: Merck & Co. Inc. Sales; 2013-2017 (US$ Billion)
Figure 61: Merck & Co. Inc. Sales by Segment; 2017 (Percentage, %)
Figure 62: Merck & Co. Inc. Sales by Region; 2017 (Percentage, %)
Figure 63: Roche Sales; 2013-2017 (US$ Billion)
Figure 64: Roche Sales by Segments; 2017 (Percentage,%)
Figure 65: Roche Sales by Region; 2017 (Percentage, %)
Figure 66: AstraZeneca Total Revenue; 2013-2017 (US$ Billion)
Figure 67: AstraZeneca Total Revenue by Region; 2017 (Percentage, %)
Table 1: PD-1/PD-L1 Inhibitors Mechanism Action and Applications
Table 2: Approved PD-1 and PD-L1 inhibitors Timeline; 2017
Table 3: Global PD-1 and PD-L1 Inhibitors Market: Competitive Landscape
Table 4: Regulatory Status of Key PD-L1 Drugs in China